Intech Investment Management LLC Purchases New Holdings in Novavax, Inc. (NASDAQ:NVAX)

Intech Investment Management LLC bought a new stake in shares of Novavax, Inc. (NASDAQ:NVAX) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 41,751 shares of the biopharmaceutical company’s stock, valued at approximately $527,000.

A number of other large investors have also made changes to their positions in NVAX. Shah Capital Management increased its position in shares of Novavax by 19.0% during the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after purchasing an additional 1,544,263 shares during the last quarter. Renaissance Technologies LLC bought a new position in Novavax in the second quarter worth approximately $14,055,000. SG Americas Securities LLC lifted its position in shares of Novavax by 940.7% during the third quarter. SG Americas Securities LLC now owns 1,154,276 shares of the biopharmaceutical company’s stock valued at $14,579,000 after purchasing an additional 1,043,363 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Novavax in the 2nd quarter worth approximately $4,592,000. Finally, Vontobel Holding Ltd. boosted its position in shares of Novavax by 110.3% in the third quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock valued at $6,296,000 after acquiring an additional 261,464 shares during the period. Institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

NVAX has been the topic of several analyst reports. B. Riley reaffirmed a “buy” rating and issued a $26.00 target price (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Jefferies Financial Group lowered their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. JPMorgan Chase & Co. lifted their price objective on Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.83.

Novavax Trading Up 1.2 %

Shares of NVAX opened at $8.72 on Monday. The business’s 50 day moving average is $10.40 and its 200 day moving average is $12.56. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The company has a market capitalization of $1.40 billion, a PE ratio of -3.86 and a beta of 2.10.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analysts’ expectations of $65.80 million. During the same period last year, the business posted ($1.26) earnings per share. The company’s revenue for the quarter was down 54.8% compared to the same quarter last year. Equities research analysts predict that Novavax, Inc. will post -1.4 earnings per share for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.